乳房切除术后前哨淋巴结微转移患者省略完成性腋窝淋巴结清扫:SENOMIC前瞻性试验结果
中位随访53个月,5年无事件生存率86.8%、癌症特异性生存率97.0%、总生存率91.6%,孤立腋窝复发14例(3.1%)。结论认为省略完成性腋窝淋巴结清扫后无事件生存极佳,尽管腋窝复发率高于既往报道,应视为常规 care。
要点
- 乳房切除伴前哨淋巴结微转移患者可省略完成性腋窝淋巴结清扫。
- 5年无事件生存86.8%、癌症特异性生存97.0%、总生存91.6%。
- 孤立腋窝复发率3.1%,高于既往报道,需长期随访验证安全性。
核心结论
- 乳房切除术后前哨淋巴结微转移患者省略完成性腋窝淋巴结清扫后无事件生存极佳,尽管孤立腋窝复发率高于既往报道。
- 省略完成性腋窝淋巴结清扫应被视为常规 care,但需长期随访验证该策略的安全性。
研究设计与样本
- 本分析选取其中接受乳房切除术的患者455例,407例未接受区域放疗。
- 主要终点为无事件生存,次要终点包括孤立腋窝复发率、癌症特异性生存和总生存。
主要发现
- 中位随访53个月(范围5–109个月)。
- 估计5年无事件生存率86.8%、癌症特异性生存率97.0%、总生存率91.6%。
- 孤立腋窝复发14例(3.1%)。
临床怎么用
- 乳房切除伴前哨淋巴结微转移患者可考虑省略完成性腋窝淋巴结清扫,不推荐区域放疗。
- 应向患者说明腋窝复发风险高于既往报道,并安排长期随访。
局限性
- 随访时间尚不足以完全验证省略完成性腋窝淋巴结清扫的长期安全性。
- 乳房切除患者中部分未接受区域放疗,可能影响复发率解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Breast cancer patients undergoing mastectomy are not well represented in studies evaluating the omission of completion axillary lymph node dissection (cALND) due to sentinel lymph node (SLN) metastases. METHODS: The prospective multicentre SENOMIC cohort trial included patients with breast cancer and SLN micrometastases between October 2013 and December 2022. Completion ALND was omitted and nodal radiotherapy discouraged. Patients undergoing mastectomy were selected for the present analysis. The primary endpoint was event-free survival. Secondary endpoints were the isolated axillary recurrence rate (ARR) and cancer-specific and overall survival. RESULTS: In the SENOMIC trial, 455 of 882 included patients underwent mastectomy, 407 of whom did not receive nodal radiotherapy. The median follow-up time was 53 (range 5-109) months. The estimated 5-year event-free, cancer-specific, and overall survival were 86.8%, 97.0% and 91.6%, respectively. Isolated axillary recurrence was found in 14 patients (3.1%). CONCLUSION: Event-free survival after omission of cALND in breast cancer patients with SLN micrometastases undergoing mastectomy was excellent, despite a higher ARR than previously reported. Long-term follow-up is important to validate the safety of this approach, but omission of cALND should be regarded as routine care.
引用
- Andersson Y, Bergkvist L, Rydén L, et al. Omitting completion axillary lymph node dissection in breast cancer patients with sentinel lymph node micrometastases undergoing mastectomy: results from the prospective SENOMIC trial. Br J Surg. 2025. PMID: 40476677. doi:10.1093/bjs/znaf111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。